Legal status · Canada
Is Bivamelagon legal in Canada?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Bivamelagon is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Bivamelagon in Canada at a glance
| Classification | Investigational, not approved |
|---|---|
| Health Canada approval status | Not approved by Health Canada; investigational |
| Human studies cited | 4 of 5 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Bivamelagon profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
Bivamelagon is being studied in registered clinical trials but has not received Health Canada marketing approval in Canada.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Bivamelagon is
An oral MC4R agonist being developed as a tablet counterpart to injected setmelanotide. A 28 person phase 2 in hypothalamic obesity completed in February 2026 with no results posted, and there is no peer reviewed publication on the compound at all.
Bivamelagon is an oral agonist of the melanocortin-4 receptor, the same receptor that setmelanotide activates by daily injection. It was discovered by LG Chem under the code LB54640 and licensed to Rhythm Pharmaceuticals, which is developing it for hypothalamic obesity, the weight gain that follows damage to the hypothalamus from tumours or their treatment.
Mechanism: In human pharmacology of the class, MC4R activation in the hypothalamus reduces appetite; this is the pathway that loss of function mutations in POMC, PCSK1 and LEPR disrupt upstream of the receptor, and that setmelanotide restores. Bivamelagon is described by its developer as a selective MC4R agonist that is orally bioavailable.
Regulatory history: Not FDA approved. Investigational; phase 2 complete in hypothalamic obesity with no results posted, open label extension enrolling (September 2026).
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for Bivamelagon at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Bivamelagon in other countries
Frequently asked questions
Is Bivamelagon legal in Canada?
No. Bivamelagon is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Can I buy Bivamelagon in Canada?
No approved product exists to buy. In Canada Bivamelagon is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Bivamelagon Health Canada approved?
No. In Canada Bivamelagon is classified as "Investigational, not approved", which is not a Health Canada marketing approval. For comparison, the US FDA status is: Not FDA approved. Investigational; phase 2 complete in hypothalamic obesity with no results posted, open label extension enrolling (September 2026).. On the evidence, 4 human studies are cited on its profile.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Bivamelagon live on its compound profile.
Bivamelagon profileThis page is general information about the regulatory status of Bivamelagon in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.